奥法木单抗联合异环磷酰胺、依托泊苷和阿糖胞苷治疗不适合移植的复发难治性弥漫大B细胞淋巴瘤患者
这项单臂研究评估了奥法木单抗联合异环磷酰胺、依托泊苷和阿糖胞苷(O-IVAC)方案在77例不适合移植的复发难治性弥漫大B细胞淋巴瘤患者中的疗效与安全性,老年患者调整剂量,主要终点总缓解率为54.5%,中位随访70个月,中位无进展生存期和事件无生存期均为16.3个月,中位总生存期22.7个月,治疗相关死亡率为15.5%。
要点
- O-IVAC方案在复发难治性弥漫大B细胞淋巴瘤中总缓解率为54.5%。
- 中位无进展生存期和事件无生存期均为16.3个月,中位总生存期22.7个月。
- 治疗相关死亡率为15.5%,年龄、ECOG体能状态和既往治疗线数是生存的独立预测因素。
核心结论
- O-IVAC在难治性人群中显示出高缓解率,是桥接至潜在治愈性治疗的有吸引力的选择。
研究设计与样本
- 单臂研究,纳入77例接受O-IVAC挽救治疗的复发难治性弥漫大B细胞淋巴瘤患者,老年患者调整剂量,最多接受6个周期治疗,主要终点为总缓解率。
主要发现
- 平均年龄56.8岁;39%的患者ECOG体能状态至少3分;78%的患者Ann Arbor分期为3或4期;58%的患者接受过一种或以上既往挽救治疗。
- O-IVAC的总缓解率为54.5%。
- 中位研究随访时间为70个月;中位无进展生存期和事件无生存期均为16.3个月;中位总生存期为22.7个月。
- 年龄、ECOG体能状态和既往治疗线数是生存的独立预测因素。
- 治疗相关死亡率为15.5%。
临床怎么用
- 作者认为O-IVAC在难治性人群中显示出高缓解率,是桥接至潜在治愈性治疗的有吸引力的选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The efficacy of salvage treatment of diffuse large B-cell lymphoma (DLBCL) patients who relapse or progress (rrDLBCL) after initial therapy is limited. Efficacy and safety of ofatumumab with iphosphamide, etoposide and cytarabine (O-IVAC) was evaluated in a single-arm study. Dosing was modified for elderly patients. Patients received up to six cycles of treatment. The primary end-point was the overall response rate (ORR). Patients were evaluated every two cycles and then six and 12 months after treatment. Other end-points included progression-free survival (PFS), event-free survival (EFS), overall survival (OS) and safety. Seventy-seven patients received salvage treatment with O-IVAC. The average age was 56.8 years; 39% had an Eastern Cooperative Oncology Group (ECOG) performance status of at least 3; 78% had disease of Ann Arbor stage 3 or 4; 58% received one or more prior salvage therapies. The ORR for O-IVAC was 54.5%. The median duration of study follow-up was 70 months. The median PFS and EFS were 16.3 months each. The median OS was 22.7 months. Age, ECOG performance status and the number of prior therapy lines were independent predictors of survival. Treatment-related mortality was 15.5%. O-IVAC showed a high response rate in a difficult-to-treat population and is an attractive treatment to bridge to potentially curative therapies.
引用
- Paszkiewicz-Kozik E, Michalski W, Taszner M, et al. Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. Br J Haematol. 2022. PMID: 35362096. doi:10.1111/bjh.18166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。